OCULAR THERAPEUTIX, INC - 10-K filing on 2016-03-10

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2015

Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders

Basic and diluted net loss per share attributable to common stockholders was calculated as follows for the years ended December 31, 2015, 2014 and 2013:


	Year Ended December 31,
	2015			2014			2013
Numerator:
Net loss	$	(39,748	)	$	(28,648	)	$	(13,317	)
Accretion of redeemable convertible preferred stock to redemption value		—			(11	)		(27	)

Net loss attributable to common stockholders	$	(39,748	)	$	(28,659	)	$	(13,344	)

Denominator:
Weighted average common shares outstanding, basic and diluted		23,244,162			10,652,865			2,609,020

Net loss per share attributable to common stockholders, basic and diluted	$	(1.71	)	$	(2.69	)	$	(5.11	)

Schedule of Antidilutive Securities, Excluded from Computation of Diluted Net Loss per Share

The Company excluded the following common stock equivalents, outstanding as of December 31, 2015, 2014 and 2013, from the computation of diluted net loss per share attributable to common stockholders for the years ended December 31, 2015, 2014 and 2013 because they had an anti-dilutive impact due to the net loss attributable to common stockholders incurred for the periods.


	December 31,
	2015		2014		2013
Options to purchase common stock		2,115,519		1,611,991		924,132
Non-vested restricted common stock		—		28,437		—
Warrants for the purchase of redeemable convertible preferred stock		—		—		51,830
Warrants for the purchase of common stock		18,939		89,708		—
Redeemable convertible preferred stock (as converted to common stock)		—		—		12,440,205

		2,134,458		1,730,136		13,416,167